GLP-1 and Amylin in the Treatment of Obesity

T Jorsal; J Rungby; F K Knop; Tina Vilsbøll Lauritsen

doi:10.1007/s11892-015-0693-3

GLP-1 and Amylin in the Treatment of Obesity

T Jorsal, J Rungby, F K Knop, Tina Vilsbøll Lauritsen

17 Citations (Scopus)

Abstract

For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

Original language	English
Article number	1
Journal	Current Diabetes Reports
Volume	16
ISSN	1534-4827
DOIs	https://doi.org/10.1007/s11892-015-0693-3
Publication status	Published - 1 Jan 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11892-015-0693-3

Cite this

@article{d5126a50d3b443c191ced92229b9ceb5,

title = "GLP-1 and Amylin in the Treatment of Obesity",

abstract = "For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.",

author = "T Jorsal and J Rungby and Knop, {F K} and Lauritsen, {Tina Vilsb{\o}ll}",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/s11892-015-0693-3",

language = "English",

volume = "16",

journal = "Current Diabetes Reports",

issn = "1534-4827",

publisher = "Springer Healthcare",

}

TY - JOUR

T1 - GLP-1 and Amylin in the Treatment of Obesity

AU - Jorsal, T

AU - Rungby, J

AU - Knop, F K

AU - Lauritsen, Tina Vilsbøll

PY - 2016/1/1

Y1 - 2016/1/1

N2 - For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

AB - For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

U2 - 10.1007/s11892-015-0693-3

DO - 10.1007/s11892-015-0693-3

M3 - Journal article

C2 - 26699764

SN - 1534-4827

VL - 16

JO - Current Diabetes Reports

JF - Current Diabetes Reports

M1 - 1

ER -

GLP-1 and Amylin in the Treatment of Obesity

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this